Avidity Biosciences Inc’s recently made public that its Chief Program Officer Gallagher Kathleen P. unloaded Company’s shares for reported $0.17 million on Mar 03 ’25. In the deal valued at $29.41 per share,5,875 shares were sold. As a result of this transaction, Gallagher Kathleen P. now holds 50,554 shares worth roughly $1.52 million.
Then, Gallagher Kathleen P. sold 5,875 shares, generating $188,918 in total proceeds. Upon selling the shares at $32.16, the Chief Program Officer now owns 50,554 shares.
Before that, KATHLEEN GALLAGHER bought 17,625 shares. Avidity Biosciences Inc shares valued at $580,391 were divested by the Officer at a price of $32.93 per share.
Scotiabank initiated its Avidity Biosciences Inc [RNA] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $70. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. RBC Capital Mkts began covering RNA with “an Outperform” recommendation on November 26, 2024. Goldman started covering the stock on September 24, 2024. It rated RNA as “a Buy”.
Price Performance Review of RNA
On Monday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -0.83% to $30.04. Over the last five days, the stock has gained 2.81%. Avidity Biosciences Inc shares have risen nearly 3.30% since the year began. Nevertheless, the stocks have risen 50.05% over the past one year. While a 52-week high of $56.00 was reached on 02/07/25, a 52-week low of $20.34 was recorded on 01/14/25. SMA at 50 days reached $30.91, while 200 days put it at $38.65.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 29.42, which if violated will result in even more drops to 28.79. On the upside, there is a resistance level at 30.70. A further resistance level may holdings at 31.35. The Relative Strength Index (RSI) on the 14-day chart is 45.66, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.04, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 58.14%. Stochastics %K at 43.49% indicates the stock is a holding.
The most recent change occurred on August 28, 2024 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $63 price target.
